Search Results for 'patients ifn'

patients ifn published presentations and documents on DocSlides.

Impact of Ocrelizumab on Cognition in Patients at Increased Risk of Developing Progressive Disease
Impact of Ocrelizumab on Cognition in Patients at Increased Risk of Developing Progressive Disease
by bikersphobia
RHB Benedict. , J de . Seze. , SL Hauser, L . Kapp...
Are (exogenous)  interferons
Are (exogenous) interferons
by amey
really necessary?. Peter . Ferenci. Medical Univer...
Overview of
Overview of
by tawny-fly
MS and Strategies for Personalized Treatment . Do...
NEDA epoch analysis of patients with relapsing multiple scl
NEDA epoch analysis of patients with relapsing multiple scl
by pamella-moone
ocrelizumab. : Results from the OPERA I and OPERA...
Treatment of Hepatitis C in patients with
Treatment of Hepatitis C in patients with
by tatyana-admore
thalassaemia. . Where . are we now?. Telaprevir ....
TURQUOISE-I
TURQUOISE-I
by natalia-silvester
OBV/PTV/r + . DSV . + RBV. OBV/PTV/r + . DSV . + ...
TURQUOISE-I
TURQUOISE-I
by marina-yarberry
OBV/PTV/r + . DSV . + RBV. OBV/PTV/r + . DSV . + ...
Diagnosis and Disease Burden
Diagnosis and Disease Burden
by alexa-scheidler
Definition. 1 of 3 rare, Philadelphia-chromosome-...
Practical management of PI therapy
Practical management of PI therapy
by TropicalParadise
in Hepatitis C . Paris . Februari. 2012. Ola . We...
FISSION Design Objective
FISSION Design Objective
by travis
Non . inferiority. of SOF + RBV : SVR. 12. (. 2-...
Page 2 of 14Kannagietal Retrovirology           2019 1623
Page 2 of 14Kannagietal Retrovirology 2019 1623
by skylar
Tax and HTLV-1 basic leucine zipper factor (HBZ) a...
Single arm Open label ≥ 
Single arm Open label ≥ 
by ellena-manuel
18 years. BMI ≥ 18 kg/m. 2. HCV genotype 2, 4, ...
SOF + RBV
SOF + RBV
by debby-jeon
SOF + RBV. Randomisation*. 1 : 1 : 1. Open-label....
Single arm
Single arm
by faustina-dinatale
Open label. ≥ . 18 years. HCV genotype 4, 5 or...
Myositis Update:
Myositis Update:
by faustina-dinatale
Treatment, Autoantibodies and More. Rare Disease ...
Direct Acting Antivirals:  What are they?  What is their pl
Direct Acting Antivirals: What are they? What is their pl
by tawny-fly
Mark Sulkowski, MD. Associate Professor of Medici...
Edited by
Edited by
by celsa-spraggs
Morris Sherman MD . BCh. PhD FRCP(C) . Associate...
Current strategies for the management of treatment naïve a
Current strategies for the management of treatment naïve a
by min-jolicoeur
Mark S. Sulkowski, MD. Medical Director, Viral He...